Merck & Co., Inc. chief financial officer Robert Davis will succeed Kenneth Frazier as CEO effective on 30 June, ushering in a new era for the pharmaceutical giant as it builds out a growth strategy to augment the cancer powerhouse Keytruda (pembrolizumab). As the CEO of Merck & Co. for a decade, Frazier shaped the company from a primary care specialist to an unexpected oncology leader at the forefront of the immuno-oncology frontier.
The company announced the leadership transition on 4 February alongside its fourth quarter/full-year 2020 sales and earnings release. A transition...
